Contract for the Provision of a Home Delivery Service for Riluzole, Ubiquinone, Midodrine and Methotrexate
key details
| Value | £2,700,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | North East |
| Deadline | 12 Oct 2018 |
| Contract start | 1 Dec 2018 |
| Contract end | 30 Nov 2021 |
| Procedure | open |
| SME suitable | No |
| OCID | ocds-b5fd17-5965ca6f-16f1-4d22-aaa5-d659b495f66c |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Alcura UK Limited | £2,700,000 | 11 Oct 2018 | active |
description
Contract for the Provision of a Home Delivery Service of medicines (Riluzole, Ubiquinone, Midodrine and Methotrexate) to patients at home over a 3 year period with an option to extend for a up to 2 further 12 months.
documents
- https://www.contractsfinder.service.gov.uk/Notice/6b7d16e0-6f1b-4121-b669-ecdba87d78b7 , tenderNotice
- https://www.delta-esourcing.com/tenders/UK-UK-Newcastle-upon-Tyne:-Pharmaceutical-products./NW9ED822CG , tenderNotice
Documents are linked, not mirrored. They are served by the publishing authority and may require registration.
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 18 May 2018 | Tender (tender) | · | 6b7d16e0-6f1b-4121-b669-ecdba87d78b7-216941 |
| 18 Oct 2018 | Award (award) | · | eb477a10-279c-4b8b-9617-315e6173dd60-247118 |
more from The Newcastle upon Tyne Hospitals NHS Foundation Trust
- Waiting Well · 29 Jul 2026
- Cardiology Insourcing · 23 Jul 2026
- Cellular Pathology · 23 Jul 2026
- Systemic Anti Cancer Therapy · 23 Jul 2026
- Paediatric Diabetes Network Support · 23 Jul 2026
- Laboratory Services Freeman Hospital · 23 Jul 2026
- Lab Services RVI - SQCL · 23 Jul 2026
- Breast Screening · 30 Jun 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.